Myasthenia Gravis Market to Reach USD 4.6 Billion by 2034

Pune, India, November 7, 2025 - The Global Myasthenia Gravis Market is projected to grow from USD 2.1 billion in 2024 to approximately USD 4.6 billion by 2034, registering a CAGR of 8.3% during the forecast period (2025-2034), according to Exactitude Consultancy. Market expansion is being driven by the increasing prevalence of autoimmune diseases, ongoing clinical research in novel biologic therapies, and improving diagnostic rates due to better healthcare infrastructure.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71325

Key Takeaways
• Market Size (2024): USD 2.1 Billion
• Forecast (2034): USD 4.6 Billion
• CAGR (2025-2034): 8.3%
• Key Segments: Treatment Type, Disease Type, Distribution Channel, and Region
• Leading Companies: Alexion Pharmaceuticals (AstraZeneca), Argenx SE, F. Hoffmann-La Roche AG, Grifols S.A., Takeda Pharmaceuticals, Novartis AG, Immunovant Inc., and Catalyst Pharmaceuticals

Market Story
Myasthenia Gravis (MG) is a chronic autoimmune neuromuscular disorder that causes weakness in skeletal muscles responsible for movement. Growing research on targeted biologics and monoclonal antibodies has significantly improved treatment efficacy and patient quality of life.

The introduction of complement inhibitors and FcRn-targeted therapies, such as Eculizumab (Soliris) and Efgartigimod (Vyvgart), has redefined the therapeutic landscape. These biologics not only provide faster symptom control but also reduce dependence on corticosteroids and other immunosuppressants.

Increasing collaborations between pharma companies and research institutions are accelerating clinical development pipelines. Moreover, global patient advocacy efforts are leading to earlier diagnosis, improved access to therapies, and inclusion of MG in rare disease programs.

Market Segmentation
By Treatment Type:
Corticosteroids, Immunosuppressants, Monoclonal Antibodies, Cholinesterase Inhibitors, Complement Inhibitors, Others

By Disease Type:
Ocular Myasthenia Gravis, Generalized Myasthenia Gravis, Congenital Myasthenic Syndromes

By Distribution Channel:
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

By Region:
North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Explore Full Report here: https://exactitudeconsultancy.com/reports/71325/myasthenia-gravis-market

Recent Developments
• Argenx SE expanded the indication of Efgartigimod (Vyvgart) for generalized MG patients across additional global markets.
• Alexion Pharmaceuticals (AstraZeneca) initiated trials for next-generation complement inhibitors with improved dosing profiles.
• Roche continued Phase III studies of Rozanolixizumab, an FcRn antagonist for MG treatment.
• Grifols S.A. advanced its immunoglobulin therapies to support long-term symptom management in MG.
• Catalyst Pharmaceuticals launched new patient access programs for its cholinesterase inhibitor Firdapse® in North America.

Expert Insight
"The global myasthenia gravis market is witnessing a paradigm shift as precision medicine and biologics take center stage. Expanded clinical pipelines and regulatory incentives are ensuring that patients with rare autoimmune diseases receive targeted, life-changing therapies,"
- Lead Rare Diseases Analyst, Exactitude Consultancy.

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71325

Market Drivers
• Rising Prevalence of Autoimmune Disorders: Increasing cases of MG and related conditions globally.
• Emergence of Targeted Biologics: FcRn inhibitors and complement pathway drugs improving efficacy and safety.
• Government & NGO Support: Rare disease frameworks expanding therapy access and reimbursement.
• R&D Investments: Surge in clinical trials and collaborations for next-generation MG treatments.

Forecast & Regional Insights
North America holds the dominant market share, accounting for over 45% in 2024, due to high awareness, availability of advanced therapeutics, and strong regulatory backing for rare disease treatment. Europe follows closely with favorable reimbursement policies and established clinical networks. The Asia-Pacific region is expected to witness the fastest CAGR of 9.1%, driven by increasing healthcare access and growing participation in multinational MG clinical trials in Japan, China, and South Korea.

Conclusion
The myasthenia gravis market is poised for sustained growth over the next decade, driven by biologic innovation, regulatory support, and digital diagnostic improvements. As the industry moves toward precision and patient-centered care, MG management will increasingly rely on advanced immunotherapies and personalized treatment protocols.

This report is also available in the following languages : Japanese (重症筋無力症市場), Korean (중증 근무력증 시장), Chinese (重症肌无力市场), French (Marché de la myasthénie grave), German (Myasthenia Gravis Markt), and Italian (Mercato della miastenia grave), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71325/myasthenia-gravis-market#request-a-sample

Related Reports

Lambert Eaton Myasthenic Syndrome Market
https://exactitudeconsultancy.com/reports/71907/lambert-eaton-myasthenic-syndrome-market

Generalized Myasthenia Gravis (gMG) Market
https://exactitudeconsultancy.com/reports/72089/generalized-myasthenia-gravis-gmg-market

Lambert-Eaton Myasthenic Syndrome (LEMS) Market
https://exactitudeconsultancy.com/reports/72090/lambert-eaton-myasthenic-syndrome-lems-market

Myasthenia Gravis Patient Pool Analysis Market
https://exactitudeconsultancy.com/reports/71623/myasthenia-gravis-patient-pool-analysis-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.